JP2005526732A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526732A5 JP2005526732A5 JP2003571283A JP2003571283A JP2005526732A5 JP 2005526732 A5 JP2005526732 A5 JP 2005526732A5 JP 2003571283 A JP2003571283 A JP 2003571283A JP 2003571283 A JP2003571283 A JP 2003571283A JP 2005526732 A5 JP2005526732 A5 JP 2005526732A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- ylamino
- thiazol
- benzoyl
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229940086609 Lipase inhibitor Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- -1 2-methyl-benzoyl Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 2
- 229960001243 orlistat Drugs 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- WUMYVSGSTKZLKN-UHFFFAOYSA-N 2,5-dimethoxy-n-[4-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]butyl]benzenesulfonamide Chemical compound COC1=CC=C(OC)C(S(=O)(=O)NCCCCNC=2SC(=CN=2)C(=O)C=2C(=CC=CC=2)C)=C1 WUMYVSGSTKZLKN-UHFFFAOYSA-N 0.000 claims 1
- OJBJPKNOXBHZGJ-UHFFFAOYSA-N 2-chloro-n-[3-[[4-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C1=CSC(NCCCNS(=O)(=O)C=2C(=CC=C(C=2)C(F)(F)F)Cl)=N1 OJBJPKNOXBHZGJ-UHFFFAOYSA-N 0.000 claims 1
- VSKXSADWIKAJOW-UHFFFAOYSA-N 2-chloro-n-[3-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]propyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=C(Cl)C(S(=O)(=O)NCCCNC=2SC(=CN=2)C(=O)C=2C(=CC=CC=2)Cl)=C1 VSKXSADWIKAJOW-UHFFFAOYSA-N 0.000 claims 1
- MOAWCMYHSCPOHS-UHFFFAOYSA-N 2-chloro-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1Cl MOAWCMYHSCPOHS-UHFFFAOYSA-N 0.000 claims 1
- WSZRBYPVRMTROP-UHFFFAOYSA-N 2-chloro-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1Cl WSZRBYPVRMTROP-UHFFFAOYSA-N 0.000 claims 1
- JFZKIMSEVKSNHD-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[3-[[4-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCNC1=NC(C(=O)C=2C(=CC=CC=2)C)=CS1 JFZKIMSEVKSNHD-UHFFFAOYSA-N 0.000 claims 1
- BFGZPYGHAVNFFS-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)C)S1 BFGZPYGHAVNFFS-UHFFFAOYSA-N 0.000 claims 1
- LNHWQOKFWISJLR-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[5-[[4-methyl-5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]pentyl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCCCNC1=NC(C)=C(C(=O)C=2C(=CC=CC=2)C)S1 LNHWQOKFWISJLR-UHFFFAOYSA-N 0.000 claims 1
- SEZOMSCCWVONAJ-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[5-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]pentyl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)C)S1 SEZOMSCCWVONAJ-UHFFFAOYSA-N 0.000 claims 1
- AKHLFPVCUFCQSQ-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[5-[[5-(pyridine-2-carbonyl)-1,3-thiazol-2-yl]amino]pentyl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2N=CC=CC=2)S1 AKHLFPVCUFCQSQ-UHFFFAOYSA-N 0.000 claims 1
- ZWLLNFYGGZRONL-UHFFFAOYSA-N 2-methyl-n-[5-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]pentyl]benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCCCNS(=O)(=O)C1=CC=CC=C1C ZWLLNFYGGZRONL-UHFFFAOYSA-N 0.000 claims 1
- KOWYRMJDDGKFPJ-UHFFFAOYSA-N 3-fluoro-n-[5-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]pentyl]benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCCCNS(=O)(=O)C1=CC=CC(F)=C1 KOWYRMJDDGKFPJ-UHFFFAOYSA-N 0.000 claims 1
- HHBPUXHVLPSPRC-UHFFFAOYSA-N 4-chloro-n-methyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]benzenesulfonamide Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N(C)CCCNC(S1)=NC=C1C(=O)C1=CC=CC=C1C HHBPUXHVLPSPRC-UHFFFAOYSA-N 0.000 claims 1
- YSYAZDMYCKSANN-UHFFFAOYSA-N 4-methoxy-n-[5-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]pentyl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)C)S1 YSYAZDMYCKSANN-UHFFFAOYSA-N 0.000 claims 1
- KINDPLVJEGXZBU-UHFFFAOYSA-N 5-chloro-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]thiophene-2-sulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC=C(Cl)S1 KINDPLVJEGXZBU-UHFFFAOYSA-N 0.000 claims 1
- MWJPZYAHWVJURU-UHFFFAOYSA-N 5-fluoro-2-methyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC(F)=CC=C1C MWJPZYAHWVJURU-UHFFFAOYSA-N 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- AOMFSYVEJWWWOZ-UHFFFAOYSA-N n,2-dimethyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]benzenesulfonamide Chemical compound C=1C=CC=C(C)C=1S(=O)(=O)N(C)CCCNC(S1)=NC=C1C(=O)C1=CC=CC=C1C AOMFSYVEJWWWOZ-UHFFFAOYSA-N 0.000 claims 1
- DWXOPSSXKDXLTE-UHFFFAOYSA-N n-[3-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]propyl]-2-methoxy-5-methylbenzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 DWXOPSSXKDXLTE-UHFFFAOYSA-N 0.000 claims 1
- ZJACVTXUARJMKK-UHFFFAOYSA-N n-[3-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]propyl]thiophene-2-sulfonamide Chemical compound ClC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC=CS1 ZJACVTXUARJMKK-UHFFFAOYSA-N 0.000 claims 1
- YFZMRHFEVGODEE-UHFFFAOYSA-N n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]thiophene-2-sulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC=CS1 YFZMRHFEVGODEE-UHFFFAOYSA-N 0.000 claims 1
- CSNICAGFSAQDIK-UHFFFAOYSA-N n-[4-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]butyl]thiophene-2-sulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCCNS(=O)(=O)C1=CC=CS1 CSNICAGFSAQDIK-UHFFFAOYSA-N 0.000 claims 1
- KYZCONUNJLEHBB-UHFFFAOYSA-N n-[5-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]pentyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 KYZCONUNJLEHBB-UHFFFAOYSA-N 0.000 claims 1
- KITOQPGNBHIXGH-UHFFFAOYSA-N n-[5-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]pentyl]-2-methoxy-5-methylbenzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 KITOQPGNBHIXGH-UHFFFAOYSA-N 0.000 claims 1
- XJTXAAPTCQPFDF-UHFFFAOYSA-N n-[5-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]pentyl]-2-methylbenzenesulfonamide Chemical compound CC1=CC=CC=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 XJTXAAPTCQPFDF-UHFFFAOYSA-N 0.000 claims 1
- LMUWHAMXLLIQOX-UHFFFAOYSA-N n-methyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]thiophene-2-sulfonamide Chemical compound C=1C=CSC=1S(=O)(=O)N(C)CCCNC(S1)=NC=C1C(=O)C1=CC=CC=C1C LMUWHAMXLLIQOX-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02004296 | 2002-02-28 | ||
| PCT/EP2003/001667 WO2003072577A1 (en) | 2002-02-28 | 2003-02-19 | Thiazole derivatives as npy receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526732A JP2005526732A (ja) | 2005-09-08 |
| JP2005526732A5 true JP2005526732A5 (enExample) | 2005-12-22 |
Family
ID=27763338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571283A Pending JP2005526732A (ja) | 2002-02-28 | 2003-02-19 | Ｎｐｙ受容体拮抗剤としてのチアゾール誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6686381B2 (enExample) |
| EP (1) | EP1480976B1 (enExample) |
| JP (1) | JP2005526732A (enExample) |
| KR (1) | KR100611854B1 (enExample) |
| CN (1) | CN100363362C (enExample) |
| AR (1) | AR038704A1 (enExample) |
| AT (1) | ATE373654T1 (enExample) |
| AU (1) | AU2003210305B2 (enExample) |
| BR (1) | BR0308108A (enExample) |
| CA (1) | CA2475299A1 (enExample) |
| DE (1) | DE60316411T2 (enExample) |
| ES (1) | ES2292992T3 (enExample) |
| GT (1) | GT200300045A (enExample) |
| MX (1) | MXPA04008379A (enExample) |
| PA (1) | PA8567301A1 (enExample) |
| PE (1) | PE20030930A1 (enExample) |
| PL (1) | PL372463A1 (enExample) |
| RU (1) | RU2004129285A (enExample) |
| TW (1) | TW200403995A (enExample) |
| UY (1) | UY27689A1 (enExample) |
| WO (1) | WO2003072577A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| WO2005014592A1 (en) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | 2-amino-5-benzoylthiazole npy antagonists |
| WO2005014593A1 (en) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Thiazole derivatives as npy antagonists |
| JP4527729B2 (ja) * | 2003-12-08 | 2010-08-18 | エフ．ホフマン−ラ ロシュ アーゲー | 新規チアゾール誘導体 |
| WO2005103022A1 (en) * | 2004-04-20 | 2005-11-03 | Transtech Pharma, Inc. | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| EP1981884B1 (en) * | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| WO2010098298A1 (ja) * | 2009-02-27 | 2010-09-02 | 塩野義製薬株式会社 | 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物 |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| EA202091763A1 (ru) | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения мастоцитоза |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| JP7818502B2 (ja) | 2019-08-12 | 2026-02-20 | デシフェラ・ファーマシューティカルズ，エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| SI4084778T1 (sl) | 2019-12-30 | 2024-01-31 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitorja amorfne kinaze in načini njihove uporabe |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| AUPN163795A0 (en) | 1995-03-10 | 1995-04-06 | DIPNALL, David | A device for extracting energy from moving water particles |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| PT1105123E (pt) | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| CA2340056C (en) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| US20010039275A1 (en) * | 2000-02-04 | 2001-11-08 | Bowler Andrew Neil | Use of 2,4-diaminothiazole derivatives |
| WO2001064675A1 (en) * | 2000-03-03 | 2001-09-07 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| EP1417188A1 (en) * | 2001-08-03 | 2004-05-12 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
-
2003
- 2003-02-19 KR KR1020047013315A patent/KR100611854B1/ko not_active Expired - Fee Related
- 2003-02-19 RU RU2004129285/04A patent/RU2004129285A/ru not_active Application Discontinuation
- 2003-02-19 AT AT03742945T patent/ATE373654T1/de not_active IP Right Cessation
- 2003-02-19 PL PL03372463A patent/PL372463A1/xx not_active Application Discontinuation
- 2003-02-19 CA CA002475299A patent/CA2475299A1/en not_active Abandoned
- 2003-02-19 WO PCT/EP2003/001667 patent/WO2003072577A1/en not_active Ceased
- 2003-02-19 MX MXPA04008379A patent/MXPA04008379A/es active IP Right Grant
- 2003-02-19 DE DE60316411T patent/DE60316411T2/de not_active Expired - Fee Related
- 2003-02-19 BR BR0308108-7A patent/BR0308108A/pt not_active IP Right Cessation
- 2003-02-19 EP EP03742945A patent/EP1480976B1/en not_active Expired - Lifetime
- 2003-02-19 JP JP2003571283A patent/JP2005526732A/ja active Pending
- 2003-02-19 ES ES03742945T patent/ES2292992T3/es not_active Expired - Lifetime
- 2003-02-19 CN CNB03804823XA patent/CN100363362C/zh not_active Expired - Fee Related
- 2003-02-19 AU AU2003210305A patent/AU2003210305B2/en not_active Ceased
- 2003-02-25 PE PE2003000182A patent/PE20030930A1/es not_active Application Discontinuation
- 2003-02-25 PA PA20038567301A patent/PA8567301A1/es unknown
- 2003-02-26 GT GT200300045A patent/GT200300045A/es unknown
- 2003-02-26 US US10/374,573 patent/US6686381B2/en not_active Expired - Fee Related
- 2003-02-26 AR ARP030100627A patent/AR038704A1/es not_active Application Discontinuation
- 2003-02-26 TW TW092104045A patent/TW200403995A/zh unknown
- 2003-02-27 UY UY27689A patent/UY27689A1/es not_active Application Discontinuation